Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 03, 2023 08:00 ET
|
Kala Pharmaceuticals, Inc.
-- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private...
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
December 27, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ...
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
November 28, 2022 16:02 ET
|
Kala Pharmaceuticals, Inc.
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 ---- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,...
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
November 28, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Ended Quarter with $52.4 million in Cash;...
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
November 01, 2022 07:30 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research,...
Kala Pharmaceuticals Announces Reverse Stock Split
October 20, 2022 07:30 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research,...
Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 19, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement...
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
August 18, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research,...